![]() ![]() If innovative therapy is limited to the later line, the curative effect will be discounted, and the patient's benefit will be limited. How to improve the prognosis of lymphoma treatment and improve the clinical cure rate has attracted the attention of the industry. Professor Ma Jun from the Harbin Institute of Hematology and Oncology said, "The latest research shows that the incidence of lymphoma in China is increasing year by year. At the same time, Yikaida® is currently the first approved CAR-T cell therapy product in China for this new indication. The approval for marketing of the drug has successfully promoted new progress in the treatment of adult large B-cell lymphoma, bringing hope to more patients who have failed or relapsed with first-line immunochemotherapy. Fosun Kite's Yikaida® added a second-line indication. Previously, there was no CAR-T cell therapy product in China for the treatment of adult large B-cell lymphoma who failed to respond to first-line immunochemotherapy or relapsed within 12 months after first-line immunochemotherapy. This also marks the official launch of Yikaida® for second-line indication. ![]() and Kite Pharma of the United States (trade name: Yikaida®) for the treatment of adult large B-cell lymphoma (r/r LBCL) ("this new indication") who failed first-line immunochemotherapy or relapsed within 12 months conditionally approved by the State Drug Administration ("NMPA"). SHANGHAI , J/PRNewswire/ - The product of Fosun Kite Biotechnology Co., Ltd., jointly established by Shanghai Fosun Pharmaceutical (Group) Co., Ltd. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |